What is Ge Healthcare Technologies Inc's earnings per share (EPS)?

Ge Healthcare Technologies Inc (GEHC) reported diluted earnings per share of $4.55 for fiscal year 2025. This represents a 4.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ge Healthcare Technologies Inc Financials

GEHC

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Ge Healthcare Technologies Inc (GEHC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GEHC FY2025 2026-04-29

Revenue growth is being preserved through cost control, while cash conversion is softening as more profit stays off the cash-flow line.

Across the last three years, net income climbed from $1.57B to $2.08B, but free cash flow slipped from $1.71B to $1.51B. The cash balance still expanded in FY2025 because financing cash flow turned positive, so the stronger liquidity position was not coming entirely from the business converting higher earnings into extra cash.

Operating margin held near 13.4% even as gross margin fell to 40.0%. That usually signals discipline below gross profit rather than a richer sales mix: SG&A and R&D dollars both eased while revenue still moved higher, offsetting weaker unit economics at the gross line.

Liquidity is materially better than it was, with cash at $4.49B and a current ratio of 1.4x. But the balance sheet remains acquisition-shaped, because goodwill at $13.49B is larger than equity at $10.38B, leaving book value more dependent on intangibles than on hard balance-sheet cushion.

Financial Health Signals

Financial Health Score 56/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ge Healthcare Technologies Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Ge Healthcare Technologies Inc has an operating margin of 13.4%, meaning the company retains $13 of operating profit per $100 of revenue. This strong profitability earns a score of 82/100, reflecting efficient cost management and pricing power. This is up from 13.3% the prior year.

Growth

Ge Healthcare Technologies Inc's revenue grew a modest 4.8% year-over-year to $20.6B. This slow but positive growth earns a score of 42/100.

Leverage

Ge Healthcare Technologies Inc has a moderate D/E ratio of 0.91. This balance of debt and equity financing earns a leverage score of 37/100.

Liquidity

Ge Healthcare Technologies Inc's current ratio of 1.37 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Ge Healthcare Technologies Inc has a free cash flow margin of 7.3%, earning a moderate score of 60/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Ge Healthcare Technologies Inc earns a strong 20.1% return on equity (ROE), meaning it generates $20 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 78/100. This is down from 23.6% the prior year.

Altman Z-Score Distress

1.79

Ge Healthcare Technologies Inc scores 1.79, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Ge Healthcare Technologies Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed

0.95x

For every $1 of reported earnings, Ge Healthcare Technologies Inc generates $0.95 in operating cash flow ($2.0B OCF vs $2.1B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

6.3x

Ge Healthcare Technologies Inc earns $6.3 in operating income for every $1 of interest expense ($2.8B vs $440.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.6B

YoY+4.8%

Ge Healthcare Technologies Inc generated $20.6B in revenue in fiscal year 2025. This represents an increase of 4.8% from the prior year.

EBITDA

$3.3B

YoY+4.2%

Ge Healthcare Technologies Inc's EBITDA was $3.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.2% from the prior year.

Net Income

$2.1B

YoY+4.6%

Ge Healthcare Technologies Inc reported $2.1B in net income in fiscal year 2025. This represents an increase of 4.6% from the prior year.

EPS (Diluted)

$4.55

YoY+4.8%

Ge Healthcare Technologies Inc earned $4.55 per diluted share (EPS) in fiscal year 2025. This represents an increase of 4.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.5B

YoY-3.2%

Ge Healthcare Technologies Inc generated $1.5B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 3.2% from the prior year.

Cash & Debt

$4.5B

YoY+56.3%

Ge Healthcare Technologies Inc held $4.5B in cash against $9.5B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.14

YoY+12.0%

Ge Healthcare Technologies Inc paid $0.14 per share in dividends in fiscal year 2025. This represents an increase of 12.0% from the prior year.

Shares Outstanding

456M

YoY-0.3%

Ge Healthcare Technologies Inc had 456M shares outstanding in fiscal year 2025. This represents a decrease of 0.3% from the prior year.

Margins & Returns

Gross Margin

40.0%

YoY-1.7pp

Ge Healthcare Technologies Inc's gross margin was 40.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.7 percentage points from the prior year.

Operating Margin

13.4%

YoY+0.1pp

Ge Healthcare Technologies Inc's operating margin was 13.4% in fiscal year 2025, reflecting core business profitability. This is up 0.1 percentage points from the prior year.

Net Margin

10.1%

YoY-0.0pp

Ge Healthcare Technologies Inc's net profit margin was 10.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.0 percentage points from the prior year.

Return on Equity

20.1%

YoY-3.5pp

Ge Healthcare Technologies Inc's ROE was 20.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.3B

YoY-3.9%

Ge Healthcare Technologies Inc invested $1.3B in research and development in fiscal year 2025. This represents a decrease of 3.9% from the prior year.

Share Buybacks

$200.0M

Ge Healthcare Technologies Inc spent $200.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$482.0M

YoY+20.2%

Ge Healthcare Technologies Inc invested $482.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 20.2% from the prior year.

GEHC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$20.6B+4.8%	$19.7B+0.6%	$19.6B+6.6%	$18.3B+4.3%	$17.6B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$8.2B+0.5%	$8.2B+3.6%	$7.9B+10.3%	$7.2B+0.1%	$7.2B
R&D Expenses	$1.3B-3.9%	$1.3B+8.8%	$1.2B+17.4%	$1.0B+25.7%	$816.0M
SG&A Expenses	$4.2B-1.0%	$4.3B-0.3%	$4.3B+17.9%	$3.6B+1.9%	$3.6B
Operating Income	$2.8B+5.3%	$2.6B+7.8%	$2.4B-3.4%	$2.5B-9.8%	$2.8B
Interest Expense	$440.0M-12.7%	$504.0M-7.0%	$542.0M+603.9%	$77.0M+92.5%	$40.0M
Income Tax	$614.0M+15.6%	$531.0M-28.5%	$743.0M+32.0%	$563.0M-6.2%	$600.0M
Net Income	$2.1B+4.6%	$2.0B+27.1%	$1.6B-18.2%	$1.9B-14.7%	$2.2B
EPS (Diluted)	$4.55+4.8%	$4.34+43.2%	$3.03-28.2%	$4.22-14.7%	$4.95

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$5.1B-10.0%	$5.7B+10.8%	$5.1B+2.7%	$5.0B+4.8%	$4.8B-10.2%	$5.3B+9.4%	$4.9B+0.5%	$4.8B
Cost of Revenue	$2.3B	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$2.0B-12.6%	$2.3B+13.6%	$2.0B+0.3%	$2.0B-1.3%	$2.0B-11.6%	$2.3B+12.3%	$2.0B+1.2%	$2.0B
R&D Expenses	$345.0M+7.1%	$322.0M+10.3%	$292.0M-3.3%	$302.0M-12.2%	$344.0M0.0%	$344.0M+8.9%	$316.0M-3.4%	$327.0M
SG&A Expenses	$1.1B+0.5%	$1.1B+6.3%	$1.0B+1.6%	$1.0B-1.1%	$1.0B-8.0%	$1.1B+9.3%	$1.0B-3.1%	$1.1B
Operating Income	$515.0M-37.7%	$827.0M+26.6%	$653.0M-0.2%	$654.0M+4.0%	$629.0M-21.5%	$801.0M+18.5%	$676.0M+11.2%	$608.0M
Interest Expense	$96.0M-9.4%	$106.0M-4.5%	$111.0M-1.8%	$113.0M+2.7%	$110.0M-9.1%	$121.0M-6.9%	$130.0M-0.8%	$131.0M
Income Tax	$94.0M-56.9%	$218.0M+21.8%	$179.0M+58.4%	$113.0M+8.7%	$104.0M+8.3%	$96.0M-42.9%	$168.0M+17.5%	$143.0M
Net Income	$389.0M-33.8%	$588.0M+31.8%	$446.0M-8.2%	$486.0M-13.8%	$564.0M-21.8%	$721.0M+53.4%	$470.0M+9.8%	$428.0M
EPS (Diluted)	$0.85	N/A	$0.98-7.5%	$1.06-13.8%	$1.23	N/A	$1.02+9.7%	$0.93

GEHC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$36.9B+11.5%	$33.1B+2.0%	$32.5B+17.8%	$27.5B	N/A
Current Assets	$12.5B+26.3%	$9.9B+5.2%	$9.4B+13.1%	$8.3B	N/A
Cash & Equivalents	$4.5B+56.3%	$2.9B+15.2%	$2.5B+73.2%	$1.4B+156.7%	$561.0M
Inventory	$2.2B+15.2%	$1.9B-1.1%	$2.0B-9.0%	$2.2B	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	$13.5B+2.7%	$13.1B+1.5%	$12.9B+1.0%	$12.8B-0.6%	$12.9B
Total Liabilities	$26.3B+7.7%	$24.4B-2.8%	$25.1B+40.1%	$17.9B	N/A
Current Liabilities	$9.1B-4.7%	$9.6B+6.4%	$9.0B+24.9%	$7.2B	N/A
Long-Term Debt	$9.5B+27.5%	$7.4B-11.7%	$8.4B+2.5%	$8.2B	N/A
Total Equity	$10.4B+22.9%	$8.4B+18.4%	$7.1B-23.8%	$9.4B-43.9%	$16.7B
Retained Earnings	$5.3B+61.9%	$3.3B+146.0%	$1.3B	$0	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$37.1B+0.6%	$36.9B+2.2%	$36.1B+1.8%	$35.5B+5.7%	$33.6B+1.5%	$33.1B-2.3%	$33.9B+6.3%	$31.9B
Current Assets	$10.4B-16.6%	$12.5B+5.1%	$11.9B+5.2%	$11.3B+16.2%	$9.7B-1.7%	$9.9B-6.9%	$10.6B+20.8%	$8.8B
Cash & Equivalents	$2.3B-49.7%	$4.5B+12.2%	$4.0B+7.2%	$3.7B+52.3%	$2.5B-14.6%	$2.9B-19.0%	$3.5B+77.8%	$2.0B
Inventory	$2.4B+5.3%	$2.2B-3.0%	$2.3B+0.9%	$2.3B+5.8%	$2.2B+11.3%	$1.9B-8.7%	$2.1B+5.0%	$2.0B
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$15.1B+11.6%	$13.5B+0.4%	$13.4B+0.2%	$13.4B+0.3%	$13.4B+1.8%	$13.1B0.0%	$13.1B+0.2%	$13.1B
Total Liabilities	$26.2B-0.3%	$26.3B+1.5%	$25.9B+1.4%	$25.5B+5.7%	$24.2B-1.1%	$24.4B-3.6%	$25.3B+6.2%	$23.9B
Current Liabilities	$8.5B-6.3%	$9.1B-9.6%	$10.1B+3.3%	$9.7B-2.2%	$10.0B+4.4%	$9.6B+10.2%	$8.7B+4.2%	$8.3B
Long-Term Debt	$10.1B+6.7%	$9.5B+14.7%	$8.3B+0.1%	$8.3B+22.4%	$6.8B-9.3%	$7.4B-20.0%	$9.3B+13.0%	$8.2B
Total Equity	$10.7B+2.8%	$10.4B+3.9%	$10.0B+2.9%	$9.7B+5.7%	$9.2B+8.8%	$8.4B+1.6%	$8.3B+6.6%	$7.8B
Retained Earnings	$5.7B+7.1%	$5.3B+12.1%	$4.7B+9.6%	$4.3B+12.7%	$3.8B+16.8%	$3.3B+27.5%	$2.6B+21.8%	$2.1B

GEHC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	$2.0B+1.6%	$2.0B-6.9%	$2.1B-1.5%	$2.1B+32.8%	$1.6B
Capital Expenditures	$482.0M+20.2%	$401.0M+3.6%	$387.0M+24.8%	$310.0M+25.0%	$248.0M
Free Cash Flow	$1.5B-3.2%	$1.6B-9.3%	$1.7B-6.0%	$1.8B+34.2%	$1.4B
Investing Cash Flow	-$1.0B-14.6%	-$914.0M-63.8%	-$558.0M-40.2%	-$398.0M+77.4%	-$1.8B
Financing Cash Flow	$617.0M+207.7%	-$573.0M-19.9%	-$478.0M+41.8%	-$822.0M-212.5%	-$263.0M
Dividends Paid	$64.0M+16.4%	$55.0M+34.1%	$41.0M	$0	$0
Share Buybacks	$200.0M	$0	$0	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$290.0M-72.4%	$1.1B+77.1%	$593.0M+530.9%	$94.0M-62.4%	$250.0M-72.6%	$913.0M+23.0%	$742.0M+723.5%	-$119.0M
Capital Expenditures	$178.0M+32.8%	$134.0M+21.8%	$110.0M+27.9%	$86.0M-43.4%	$152.0M+49.0%	$102.0M+13.3%	$90.0M+40.6%	$64.0M
Free Cash Flow	$112.0M-87.8%	$916.0M+89.6%	$483.0M+5937.5%	$8.0M-91.8%	$98.0M-87.9%	$811.0M+24.4%	$652.0M+456.3%	-$183.0M
Investing Cash Flow	-$2.5B-829.4%	-$269.0M-81.8%	-$148.0M+33.6%	-$223.0M+45.2%	-$407.0M-69.6%	-$240.0M-75.2%	-$137.0M+60.7%	-$349.0M
Financing Cash Flow	$21.0M+107.2%	-$293.0M-77.6%	-$165.0M-112.1%	$1.4B+575.9%	-$286.0M+77.6%	-$1.3B-239.7%	$914.0M+1703.5%	-$57.0M
Dividends Paid	$16.0M0.0%	$16.0M-50.0%	$32.0M+100.0%	$16.0M0.0%	$16.0M+14.3%	$14.0M0.0%	$14.0M0.0%	$14.0M
Share Buybacks	$100.0M	$0-100.0%	$100.0M0.0%	$100.0M	$0	$0	$0	N/A

GEHC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	40.0%-1.7pp	41.7%+1.2pp	40.5%+1.4pp	39.1%-1.7pp	40.8%
Operating Margin	13.4%+0.1pp	13.3%+0.9pp	12.4%-1.3pp	13.8%-2.1pp	15.9%
Net Margin	10.1%-0.0pp	10.1%+2.1pp	8.0%-2.4pp	10.4%-2.3pp	12.8%
Return on Equity	20.1%-3.5pp	23.6%+1.6pp	22.0%+1.5pp	20.5%+7.0pp	13.5%
Return on Assets	5.7%-0.4pp	6.0%+1.2pp	4.8%-2.1pp	7.0%	N/A
Current Ratio	1.37+0.3	1.04-0.0	1.05-0.1	1.16	N/A
Debt-to-Equity	0.91+0.0	0.88-0.3	1.18+0.3	0.88	N/A
FCF Margin	7.3%-0.6pp	7.9%-0.9pp	8.8%-1.2pp	9.9%+2.2pp	7.7%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	38.5%-1.2pp	39.7%+1.0pp	38.7%-0.9pp	39.6%-2.5pp	42.1%-0.6pp	42.8%+1.1pp	41.7%+0.3pp	41.4%
Operating Margin	10.0%-4.5pp	14.5%+1.8pp	12.7%-0.4pp	13.1%-0.1pp	13.2%-1.9pp	15.1%+1.2pp	13.9%+1.3pp	12.6%
Net Margin	7.6%-2.7pp	10.3%+1.7pp	8.7%-1.0pp	9.7%-2.1pp	11.8%-1.7pp	13.6%+3.9pp	9.7%+0.8pp	8.8%
Return on Equity	3.6%-2.0pp	5.7%+1.2pp	4.5%-0.5pp	5.0%-1.1pp	6.1%-2.4pp	8.5%+2.9pp	5.7%+0.2pp	5.5%
Return on Assets	1.1%-0.5pp	1.6%+0.4pp	1.2%-0.1pp	1.4%-0.3pp	1.7%-0.5pp	2.2%+0.8pp	1.4%+0.0pp	1.3%
Current Ratio	1.22-0.2	1.37+0.2	1.18+0.0	1.16+0.2	0.98-0.1	1.04-0.2	1.23+0.2	1.06
Debt-to-Equity	0.95+0.0	0.91+0.1	0.83-0.0	0.85+0.1	0.74-0.1	0.88-0.2	1.12+0.1	1.06
FCF Margin	2.2%-13.9pp	16.1%+6.7pp	9.4%+9.2pp	0.2%-1.9pp	2.1%-13.2pp	15.2%+1.8pp	13.4%+17.2pp	-3.8%

Similar Companies

$30.6B

$10.3B

$4.0B

$7.9B

Waystar Holding Corp. WAY

$4.4B

Frequently Asked Questions

What is Ge Healthcare Technologies Inc's annual revenue?

Ge Healthcare Technologies Inc (GEHC) reported $20.6B in total revenue for fiscal year 2025. This represents a 4.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ge Healthcare Technologies Inc's revenue growing?

Ge Healthcare Technologies Inc (GEHC) revenue grew by 4.8% year-over-year, from $19.7B to $20.6B in fiscal year 2025.

Is Ge Healthcare Technologies Inc profitable?

Yes, Ge Healthcare Technologies Inc (GEHC) reported a net income of $2.1B in fiscal year 2025, with a net profit margin of 10.1%.

What is Ge Healthcare Technologies Inc's EBITDA?

Ge Healthcare Technologies Inc (GEHC) had EBITDA of $3.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Ge Healthcare Technologies Inc have?

As of fiscal year 2025, Ge Healthcare Technologies Inc (GEHC) had $4.5B in cash and equivalents against $9.5B in long-term debt.

What is Ge Healthcare Technologies Inc's gross margin?

Ge Healthcare Technologies Inc (GEHC) had a gross margin of 40.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Ge Healthcare Technologies Inc's operating margin?

Ge Healthcare Technologies Inc (GEHC) had an operating margin of 13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ge Healthcare Technologies Inc's net profit margin?

Ge Healthcare Technologies Inc (GEHC) had a net profit margin of 10.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Ge Healthcare Technologies Inc pay dividends?

Yes, Ge Healthcare Technologies Inc (GEHC) paid $0.14 per share in dividends during fiscal year 2025.

What is Ge Healthcare Technologies Inc's return on equity (ROE)?

Ge Healthcare Technologies Inc (GEHC) has a return on equity of 20.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ge Healthcare Technologies Inc's free cash flow?

Ge Healthcare Technologies Inc (GEHC) generated $1.5B in free cash flow during fiscal year 2025. This represents a -3.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ge Healthcare Technologies Inc's operating cash flow?

Ge Healthcare Technologies Inc (GEHC) generated $2.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ge Healthcare Technologies Inc's total assets?

Ge Healthcare Technologies Inc (GEHC) had $36.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ge Healthcare Technologies Inc's capital expenditures?

Ge Healthcare Technologies Inc (GEHC) invested $482.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ge Healthcare Technologies Inc spend on research and development?

Ge Healthcare Technologies Inc (GEHC) invested $1.3B in research and development during fiscal year 2025.

Does Ge Healthcare Technologies Inc buy back shares?

Yes, Ge Healthcare Technologies Inc (GEHC) spent $200.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Ge Healthcare Technologies Inc have outstanding?

Ge Healthcare Technologies Inc (GEHC) had 456M shares outstanding as of fiscal year 2025.

What is Ge Healthcare Technologies Inc's current ratio?

Ge Healthcare Technologies Inc (GEHC) had a current ratio of 1.37 as of fiscal year 2025, which is considered adequate.

What is Ge Healthcare Technologies Inc's debt-to-equity ratio?

Ge Healthcare Technologies Inc (GEHC) had a debt-to-equity ratio of 0.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ge Healthcare Technologies Inc's return on assets (ROA)?

Ge Healthcare Technologies Inc (GEHC) had a return on assets of 5.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ge Healthcare Technologies Inc's Altman Z-Score?

Ge Healthcare Technologies Inc (GEHC) has an Altman Z-Score of 1.79, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ge Healthcare Technologies Inc's Piotroski F-Score?

Ge Healthcare Technologies Inc (GEHC) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ge Healthcare Technologies Inc's earnings high quality?

Ge Healthcare Technologies Inc (GEHC) has an earnings quality ratio of 0.95x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ge Healthcare Technologies Inc cover its interest payments?

Ge Healthcare Technologies Inc (GEHC) has an interest coverage ratio of 6.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ge Healthcare Technologies Inc?

Ge Healthcare Technologies Inc (GEHC) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.